Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma
0 Views
administrator
07/09/23
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J Schuster, Nancy L Bartlett, Sarit Assouline, Sung-Soo Yoon, et al.
Recorded @ ASH 2019 Press Briefing Saturday, December 7: CAR-T and Beyond: Therapeutic Advances for the Treatment of Blood Cancers.
More info: http://oncoletter.ch
-
Category
Show more
Facebook Comments
No comments found